☆ 4.6 Review

Targeting ARID1A-Deficient Cancers: An Immune-Metabolic Perspective

CELLS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Oncology

Metabolic programming and immune suppression in the tumor microenvironment

Emily N. Arner et al.

Summary: Increased glucose metabolism and uptake are characteristic of many tumors and used clinically to diagnose and monitor cancer progression. Cooperation and competition between different cell populations within the tumor microenvironment (TME) drive tumor proliferation, progression, metastasis, and immune evasion. Targeting metabolic heterogeneity within the TME may offer therapeutic opportunities to overcome immune suppression and enhance immunotherapies.

CANCER CELL (2023)

添加到收藏夹

Review Oncology

Mechanisms driving the immunoregulatory function of cancer cells

Antoinette van Weverwijk et al.

Summary: Tumours exhibit a wide range of variations in the distribution, composition, and activation state of immune cells, which affect their progression and response to immunotherapy. Understanding the mechanisms that regulate the diversity and function of immune cells in the tumour microenvironment will lead to the development of more targeted immunomodulatory strategies for the benefit of cancer patients.

NATURE REVIEWS CANCER (2023)

添加到收藏夹

Article Oncology

Chromatin Remodeling Induced by ARID1A Loss in Lung Cancer Promotes Glycolysis and Confers JQ1 Vulnerability

Xiaoyu Liu et al.

Summary: This study uncovers the role of ARID1A in promoting glycolysis in lung cancer and demonstrates the preclinical efficacy of BET inhibitor therapy in combating tumor growth.

CANCER RESEARCH (2022)

添加到收藏夹

Article Oncology

Somatic and Germline Genomic Alterations in Very Young Women with Breast Cancer

Adrienne G. Waks et al.

Summary: The study identified significant differences in somatic alterations of three genes (PIK3CA, GATA3, and ARID1A) in young versus older women with luminal A breast cancer. Additionally, a portion of young women with breast cancer carried pathogenic germline variants, with BRCA1/2 mutations being the most common. Further investigation into these genetic differences may help improve treatment options for young patients with breast cancer.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Immunology

Arid1a promotes thymocyte development through β-selection-dependent and β-selection-independent mechanisms

Xiaofeng Yang et al.

Summary: The study reveals that Arid1a plays an important role in T cell development, with its deletion causing developmental blocks and cell death. Arid1a controls early T cell development by maintaining intracellular TCR beta expression and activating cell survival pathways.

IMMUNOLOGY (2022)

添加到收藏夹

Review Cell Biology

Metabolic programs tailor T cell immunity in viral infection, cancer, and aging

Sofie Hedlund Moller et al.

Summary: This review summarizes recent advances in understanding the role of metabolism and epigenetics in determining the fate and function of T cells, and discusses strategies for improving T cell dysfunction through metabolic and epigenetic modulation.

CELL METABOLISM (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Roles of ARID1A variations in colorectal cancer: a collaborative review

Shankun Zhao et al.

Summary: ARID1A variations play an important role in colorectal cancer, functioning as a tumor suppressor and a prognostic factor. This review summarizes the clinical implications and molecular pathogenesis of ARID1A variations in CRC.

MOLECULAR MEDICINE (2022)

添加到收藏夹

Review Immunology

Epigenetic regulation of T cell exhaustion

Julia A. Belk et al.

Summary: This review article examines the epigenetic underpinnings of T cell exhaustion during viral infections, cancer, autoimmunity, and T cell therapies. It discusses the technologies used to study the epigenome and highlights emerging multi-omic and genome engineering approaches for investigating T cell exhaustion and potential therapeutic opportunities.

NATURE IMMUNOLOGY (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

PLK1 inhibition selectively induces apoptosis in ARID1A deficient cells through uncoupling of oxygen consumption from ATP production

Upadhyayula S. Srinivas et al.

Summary: Inhibitors of PLK1, a mitotic kinase, have objective responses in refractory cancers. However, PLK1 overexpression in cancer does not correlate with drug sensitivity. Through a chemical screen, we found that cells deficient in ARID1A tumor suppressor are highly sensitive to PLK1 inhibition, which is unrelated to canonical PLK1 functions. A CRISPR screen revealed that sensitivity in ARID1A deficient cells is dependent on the mitochondrial translation machinery. These findings highlight a new role for PLK1 in maintaining mitochondrial fitness under metabolic stress and offer a strategy for the therapeutic use of PLK1 inhibitors.

ONCOGENE (2022)

添加到收藏夹

Review Endocrinology & Metabolism

Therapeutic opportunities to modulate immune tolerance through the metabolism-chromatin axis

Anne Lise Ferrara et al.

Summary: Immune tolerance, the ability of the immune system to differentiate between external stimuli and self-components, is achieved through coordinated events involving immune cells. CD4(+)CD25(+) T regulatory cells play a crucial role in balancing immune homeostasis and function. It has been observed that energy metabolites can influence T cell fate and function through epigenetic modifications. Changes in cellular metabolism, immune pathways, and epigenetic remodeling are involved in fine-tuning the balance between T cell activation and tolerance.

TRENDS IN ENDOCRINOLOGY AND METABOLISM (2022)

添加到收藏夹

Review Immunology

Turning cold tumors hot: from molecular mechanisms to clinical applications

Jiahui Zhang et al.

Summary: Immune checkpoint blockade therapies have shown clinical benefit, but many immune-cold solid tumors do not respond. Understanding the mechanisms of cold to hot tumor transition and tumor immunotyping can provide insights for effective therapeutic strategies against cancer.

TRENDS IN IMMUNOLOGY (2022)

添加到收藏夹

Review Cell Biology

Metabolic reprogramming and epigenetic modifications on the path to cancer

Linchong Sun et al.

Summary: Metabolic rewiring and epigenetic remodeling, which are closely linked in cancer development, play important roles in tumor progression and immune escape. Metabolites can affect the function of chromatin-modifying enzymes, influencing processes such as tumor progression and immunosurveillance.

PROTEIN & CELL (2022)

添加到收藏夹

Article Oncology

Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence

Julia A. Belk et al.

Summary: This study demonstrates that modulation of chromatin remodeling complexes improves the persistence of T cells in tumors and enhances antitumor immunity, providing important insights into the genetic regulators of T cell exhaustion.

CANCER CELL (2022)

添加到收藏夹

Article Cell Biology

Abnormal microglial polarization induced by Arid1a deletion leads to neuronal differentiation deficits

Maolei Gong et al.

Summary: In this study, we identified ARID1A as a central regulator of microglia polarization and established a mechanistic link between chromatin remodeling, neurogenesis, and mouse behaviors, highlighting the potential development of innovative therapeutics exploiting the innate regenerative capacity of the nervous system.

CELL PROLIFERATION (2022)

添加到收藏夹

Article Cell Biology

Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment

Nicole Kirchhammer et al.

Science Translational Medicine (2022)

添加到收藏夹

Article Multidisciplinary Sciences

ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression

Ni Li et al.

Summary: Loss of ARID1A promotes prostate cancer progression and immunosuppression by promoting the infiltration of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs). Inflammatory cues activate IKK beta to phosphorylate ARID1A and degrade it, leading to CXCR2 ligand-mediated PMN-MDSC chemotaxis. Neutralization of PMN-MDSCs restricts the progression of ARID1A-deficient tumors.

NATURE COMMUNICATIONS (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Subtype of Neuroblastoma Cells with High KIT Expression Are Dependent on KIT and Its Knockdown Induces Compensatory Activation of Pro-Survival Signaling

Timofey Lebedev et al.

Summary: Neuroblastoma is a pediatric cancer with high clinical and molecular heterogeneity, and patients with high-risk tumors have limited treatment options. Receptor tyrosine kinase KIT has been identified as a potential marker of high-risk neuroblastoma and a promising target for neuroblastoma treatment. Increased KIT expression is associated with activation of cell survival pathways, downregulated apoptosis induction, and cell cycle checkpoint control pathways.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Microglia homeostasis mediated by epigenetic ARID1A regulates neural progenitor cells response and leads to autism-like behaviors

Libo Su et al.

Summary: Microglial homeostasis and neural progenitor cell signal transduction show a significant interplay during embryonic neurogenesis. ARID1A disrupts the chromatin landscape of microglia, affecting microglial state switching. The perturbation of microglial homeostasis impairs PRG3 release, which impacts neural progenitor cell self-renewal and differentiation during embryonic development. Loss of microglia-driven PRG3 leads to misregulation in the downstream cascade of the Wnt/beta-catenin signaling pathway, resulting in abnormal neuronal development and autism-like behaviors at later stages.

MOLECULAR PSYCHIATRY (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age

Birgit Burkhardt et al.

Summary: This study compares mutational profiles in different age groups of Burkitt lymphoma patients and finds a transition in mutational features between the ages of 25 and 40. There are also differences in the mutation frequencies between pediatric and adult patients. TP53 mutations in pediatric patients are significantly associated with higher relapse incidence.

NATURE COMMUNICATIONS (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

AMPK: An odyssey of a metabolic regulator, a tumor suppressor, and now a contextual oncogene

Vasudevarao Penugurti et al.

Summary: Metabolic reprogramming is a biochemical adaptation that allows solid tumors to tolerate various stresses. Adenosine monophosphate (AMP)-activated protein kinase (AMPK) plays a crucial role in regulating cellular metabolism and energy balance. While AMPK was initially considered a tumor suppressor, recent studies have revealed its oncogenic potential. Therefore, the combination of AMPK inhibitors with anti-metabolite drugs is a promising approach to treat AMPK-driven cancers.

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2022)

添加到收藏夹

Article Oncology

Epigenetic gene alterations in metastatic solid tumours: results from the prospective precision medicine MOSCATO and MATCH-R trials

Patricia Martin-Romano et al.

Summary: The study aimed to describe the presence of epigenetic gene alterations in metastatic solid tumours and found these alterations to be frequent, with common changes in genes like KMT2D and KMT2C. Some EGAs were found to co-occur with driver gene alterations, but no correlation was observed between the presence of EGA and patient outcomes.

EUROPEAN JOURNAL OF CANCER (2022)

添加到收藏夹

Article Oncology

Metabolic and epigenetic orchestration of (CAR) T cell fate and function

Behnia Akbari et al.

Summary: This article focuses on the functional impairments of CAR T cells in tumor microenvironments, where tumor cell metabolism and nutrient competition affect the differentiation and function of CAR T cells' progeny. Metabolic intermediates shape the immune response by influencing epigenetic programs.

CANCER LETTERS (2022)

添加到收藏夹

Review Cell Biology

Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response

Jayaprakash Mandal et al.

Summary: Chromatin remodeling is a crucial cellular process that plays a key role in cell function. ARID1A is the most commonly mutated chromatin remodeling gene and is closely associated with cancer development. Deficiency in ARID1A leads to tumor progression and dissemination. PARP inhibitors can be used as a therapeutic approach for ARID1A-mutated tumors.

JOURNAL OF BIOMEDICAL SCIENCE (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Targeting USP9X-AMPK Axis in ARID1A-Deficient Hepatocellular Carcinoma

Feng-Kun Zhang et al.

Summary: The loss of ARID1A in hepatocellular carcinoma (HCC) cells provides protection against cell death induced by glucose deprivation. ARID1A regulates the USP9X-AMPK axis, and synthetic lethal therapy targeting USP9X may benefit HCC patients with ARID1A mutation.

CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY (2022)

添加到收藏夹

Article Oncology

GLS1 is a Protective Factor in Patients with Ovarian Clear Cell Carcinoma and its Expression Does Not Correlate with ARID1A-mutated Tumors

Valentino Clemente et al.

Summary: Targeting glutamine metabolism has been proposed as a therapeutic strategy for ovarian cancer, and the kidney isoform of glutaminase, GLS1, has emerged as a potential target. CB839, a first-in-class GLS1 inhibitor, has shown promise in clinical trials and is being investigated in platinum-resistant ovarian cancer patients. In OCCC, the presence of ARID1A mutations has been suggested to drive GLS1 expression and metabolism reprogramming. However, our study found that GLS1 overexpression was not correlated with ARID1A loss in clinical specimens of OCCC, and was associated with better clinical outcomes. This suggests that blockade of GLS1 may not be beneficial for OCCC patients.

CANCER RESEARCH COMMUNICATIONS (2022)

添加到收藏夹

Review Pharmacology & Pharmacy

Polo-like Kinase 1 as an emerging drug target: structure, function and therapeutic implications

Ilma Shakeel et al.

Summary: PLK1, a conserved mitotic serine-threonine protein kinase, plays important roles in cell division and genome stability. Its expression is controlled by cell cycle stages and blocking PLK1 expression can inhibit tumor cell proliferation and induce apoptosis, making it an attractive target for drug development.

JOURNAL OF DRUG TARGETING (2021)

添加到收藏夹

Article Oncology

ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer

Amir Mehrvarz Sarshekeh et al.

Summary: Mutations in ARID1A in colorectal cancer lead to increased tumor mutational burden and frameshift mutations, resulting in higher levels of neoantigens and enhanced immune activity. Tumors with ARID1A mutations may be more responsive to immune therapy-based treatment strategies and should be recognized as a distinct molecular subgroup.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Epigenetic modulation of antitumor immunity for improved cancer immunotherapy

Enyong Dai et al.

Summary: Epigenetic mechanisms play important roles in cancer initiation and immune cell function, with the potential to impact tumor microenvironment and therapeutic efficacy by modulating immune cell populations and promoting transcriptional and metabolic reprogramming. By regulating immune-associated genes and immune checkpoint molecules, epigenetic modulating agents can enhance tumor immunogenicity and facilitate anti-tumor immune responses.

MOLECULAR CANCER (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Inability to switch from ARID1A-BAF to ARID1B-BAF impairs exit from pluripotency and commitment towards neural crest formation in ARID1B-related neurodevelopmental disorders

Luca Pagliaroli et al.

Summary: The ARID1B subunit of the BAF chromatin remodeling complex is crucial for neurodevelopment and its dysfunction is associated with Coffin-Siris syndrome. Research shows that there is a transition from ARID1A-containing complexes to ARID1B during cranial neural crest cell differentiation, which regulates pluripotency exit and lineage commitment by coordinating the NANOG and SOX2 networks. Failure in this transition can lead to impaired CNCC formation in Coffin-Siris patients, suggesting a pathogenic mechanism for the syndrome.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Review Oncology

The Role of ARID1A in Tumors: Tumor Initiation or Tumor Suppression?

Shouying Xu et al.

Summary: ARID1A gene mutations are common in human cancers and play crucial roles in tumor initiation and suppression. ARID1A is involved in tumor progression through modulation of cell cycle, cellular functions, and signaling pathways. Mutations affecting SWI/SNF complex subunits also promote cancer development.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Review Cell Biology

Interplay Among Metabolism, Epigenetic Modifications, and Gene Expression in Cancer

Miaomiao Huo et al.

Summary: Epigenetic modifications and metabolism play crucial roles in tumorigenesis and cancer development, with complex interactions between the two processes. Understanding the crosstalk among metabolism, epigenetic modifications, and gene expression can provide insights into the mechanisms of carcinogenesis and progression to metastasis.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

添加到收藏夹

Review Oncology

Targeting ARID1A mutations in cancer

Jaren Mullen et al.

Summary: Mutations in ARID1A, a subunit gene of the SWI/SNF chromatin remodeling complex, are common in various cancers and play a crucial role in regulating gene expression related to oncogenesis and tumor suppression. Targeting ARID1A-altered cancers may involve a combination of immune checkpoint blockade and inhibitors of various pathways.ARID1A alterations may also mediate resistance to specific chemotherapies and hormone therapies.

CANCER TREATMENT REVIEWS (2021)

添加到收藏夹

Review Oncology

ARID1A Variations in Cholangiocarcinoma: Clinical Significances and Molecular Mechanisms

Shankun Zhao et al.

Summary: ARID1A variation in CCA is common and may serve as a tumor suppressor and prognostic indicator. Multiple molecular mechanisms are involved in the relationship between ARID1A variations and the pathogenesis and pathophysiology of CCA, including disruption of the cell cycle, chromatin remodeling, and DNA hypermethylation.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Medicine, Research & Experimental

SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer

Gregory P. Botta et al.

Summary: A subset of patients with pancreatic cancer harboring SWI/SNF chromatin remodeling gene alterations appear to be responsive to ICIs, achieving complete remission in some cases. Prospective trials are needed to validate these findings.

JCI INSIGHT (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Cancer gene mutation frequencies for the US population

Gaurav Mendiratta et al.

Summary: Mutations play a fundamental role in cancer development, generating targetable vulnerabilities; estimates of gene mutation frequencies in the US cancer population were made using genomic and epidemiological data; high-frequency, high-profile cancer driver genes do not dominate cancer genetics as previously suggested.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Review Immunology

CD8+ T cell metabolism in infection and cancer

Miguel Reina-Campos et al.

Summary: CD8(+) T cells play a crucial role in eliminating intracellular infections and malignant cells, with their metabolism being influenced by extracellular metabolites and immunological signals. Both intrinsic and extrinsic metabolic cues can contribute to CD8(+) T cell dysfunction, and overall host metabolism can also impact the CD8(+) T cell response.

NATURE REVIEWS IMMUNOLOGY (2021)

添加到收藏夹

Article Oncology

Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma

Shuai Wu et al.

Summary: Mutations in components of the SWI/SNF chromatin remodeling complex, such as ARID1A, lead to a dependence on glutamine metabolism. Inactivation of ARID1A upregulates GLS1, increasing glutamine utilization and metabolism to support aspartate synthesis. Pharmacological inhibition of glutaminase with CB-839 alone or in combination with immune checkpoint blockade shows promise as a therapeutic strategy for cancers with SWI/SNF complex alterations, including ARID1A mutations.

NATURE CANCER (2021)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Synthetic lethality as an engine for cancer drug target discovery

Alan Huang et al.

NATURE REVIEWS DRUG DISCOVERY (2020)

添加到收藏夹

Article Oncology

ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy

Ryosuke Okamura et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Article Nanoscience & Nanotechnology

Combined Delivery of Temozolomide and siPLK1 Using Targeted Nanoparticles to Enhance Temozolomide Sensitivity in Glioma

Hui Shi et al.

INTERNATIONAL JOURNAL OF NANOMEDICINE (2020)

添加到收藏夹

Article Medicine, Research & Experimental

Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy

Jing Li et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

添加到收藏夹

Review Oncology

The SWI/SNF complex in cancer - biology, biomarkers and therapy

Priya Mittal et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Cell Biology

ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC

Sangeeta Goswami et al.

SCIENCE TRANSLATIONAL MEDICINE (2020)

添加到收藏夹

Review Immunology

The Contribution of Epigenetics to Cancer Immunotherapy

Lorea Villanueva et al.

TRENDS IN IMMUNOLOGY (2020)

添加到收藏夹

Article Medicine, Research & Experimental

Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors

Lulu Wang et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Targeting the epigenetic regulation of antitumour immunity

Simon J. Hogg et al.

NATURE REVIEWS DRUG DISCOVERY (2020)

添加到收藏夹

Article Oncology

Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers

Hideaki Ogiwara et al.

CANCER CELL (2019)

添加到收藏夹

Article Oncology

Chromatin remodeling mediated by ARID1A is indispensable for normal hematopoiesis in mice

Lin Han et al.

LEUKEMIA (2019)

添加到收藏夹

Article Multidisciplinary Sciences

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens

Fiona M. Behan et al.

NATURE (2019)

添加到收藏夹

Article Oncology

HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer

Takeshi Fukumoto et al.

CANCER RESEARCH (2019)

添加到收藏夹

Article Cell & Tissue Engineering

A Homeostatic Arid1a-Dependent Permissive Chromatin State Licenses Hepatocyte Responsiveness to Liver-Injury-Associated YAP Signaling

Weiping Li et al.

CELL STEM CELL (2019)

添加到收藏夹

Article Oncology

Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy

Youngran Park et al.

CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer

Yonathan Lissanu Deribe et al.

NATURE MEDICINE (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade

Jianfeng Shen et al.

NATURE MEDICINE (2018)

添加到收藏夹

Article Oncology

The clinical significance of PD-L1 in advanced gastric cancer is dependent on ARID1A mutations and ATM expression

Simonetta Buglioni et al.

ONCOIMMUNOLOGY (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

Moshe Sade-Feldman et al.

CELL (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration

James M. McFarland et al.

NATURE COMMUNICATIONS (2018)

添加到收藏夹

Review Genetics & Heredity

Metabolism and Epigenetic Interplay in Cancer: Regulation and Putative Therapeutic Targets

Vera Miranda-Goncalves et al.

FRONTIERS IN GENETICS (2018)

添加到收藏夹

Article Cell Biology

ARID1A-mutated ovarian cancers depend on HDAC6 activity

Benjamin G. Bitler et al.

NATURE CELL BIOLOGY (2017)

添加到收藏夹

Article Oncology

Arid1a Has Context-Dependent Oncogenic and Tumor Suppressor Functions in Liver Cancer

Xuxu Sun et al.

CANCER CELL (2017)

添加到收藏夹

Article Biochemistry & Molecular Biology

Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening

E. Robert McDonald et al.

CELL (2017)

添加到收藏夹

Article Oncology

The Clinicopathologic Significance of BAF250a (ARID1A) Expression in Hepatocellular Carcinoma

Jie Zhao et al.

PATHOLOGY & ONCOLOGY RESEARCH (2016)

添加到收藏夹

Article Genetics & Heredity

The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis

William J. Gibson et al.

NATURE GENETICS (2016)

添加到收藏夹

Article Multidisciplinary Sciences

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A

Chris T. Williamson et al.

NATURE COMMUNICATIONS (2016)

添加到收藏夹

Article Oncology

Glutathione and Thioredoxin Antioxidant Pathways Synergize to Drive Cancer Initiation and Progression

Isaac S. Harris et al.

CANCER CELL (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets

Agnieszka K. Witkiewicz et al.

NATURE COMMUNICATIONS (2015)

添加到收藏夹

Article Oncology

ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors

Jianfeng Shen et al.

CANCER DISCOVERY (2015)

添加到收藏夹

Article Biochemistry & Molecular Biology

ARID1B is a specific vulnerability in ARID1A-mutant cancers

Katherine C. Helming et al.

NATURE MEDICINE (2014)

添加到收藏夹

Article Genetics & Heredity

Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma

Mark Sausen et al.

NATURE GENETICS (2013)

添加到收藏夹

Review Oncology

ARID1A Mutations in Cancer: Another Epigenetic Tumor Suppressor?

Jennifer N. Wu et al.

CANCER DISCOVERY (2013)

添加到收藏夹

Article Oncology

Use of mutation profiles to refine the classification of endometrial carcinomas

Melissa K. McConechy et al.

JOURNAL OF PATHOLOGY (2012)

添加到收藏夹

Article Genetics & Heredity

Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators

Akihiro Fujimoto et al.

NATURE GENETICS (2012)

添加到收藏夹

Article Genetics & Heredity

Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma

Cecile Guichard et al.

NATURE GENETICS (2012)

添加到收藏夹

Article Genetics & Heredity

Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer

Kai Wang et al.

NATURE GENETICS (2011)

添加到收藏夹

Article Multidisciplinary Sciences

Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma

Sian Jones et al.

SCIENCE (2010)

添加到收藏夹

Article Multidisciplinary Sciences

ES cell pluripotency and germ-layer formation require the SWI/SNF chromatin remodeling component BAF250a

Xiaolin Gao et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.